Stocks and Finance

NeurogesX

NeurogesX 2/9/2012

14:39 : A FDA panel votes 12 to 0 that the Qutenza patch offered by NeurogesX ... - A FDA panel votes 12 to 0 that the Qutenza patch offered by NeurogesX (NGSX) doesn't treat pain in patients afflicted with HIV. Shares are still under a trading halt. Post your comment!
Source : seekingalpha-com

NeurogesX 1/4/2012

18:19 : NeurogesX picks former Poniard boss as president, CEO - Former Poniard Pharmaceuticals CEO Ron Martell replaced the retired Tony DiTonno as president and CEO of pain treatment developer NeurogesX Inc. Martell’s base salary is $460,000, compared to a 2010 base salary of $440,214 at Poniard. ...
Source : bizjournals-com

NeurogesX 6/16/2011

09:58 : NeurogesX soars on drug update - BOSTON (MarketWatch) -- Shares of NeurogesX Inc. soared 21% to stand at $3.23 early Thursday following news that it has completed enrollment in a Phase II clinical trial for its drug NGX-1998, a topical formulation of the pain reliever ...
Source : marketwatch-com
actualidad NeurogesX -


Biotechnology

Pharmaceuticals

Medical Supplies

Medical Equipment

Health Care Providers

Copyright © 2009 Finaperf.com - Exchange rate - Investir - Stock Exchange - Börse - Finanças - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts